Current and prospective pharmacological targets in relation to antimigraine action
Migraine is a recurrent incapacitating neurovascular disorder characterized by unilateral and throbbing headaches associated with photophobia, phonophobia, nausea, and vomiting. Current specific drugs used in the acute treatment of migraine interact with vascular receptors, a fact that has raised concerns about their cardiovascular safety. In the past, alpha-adrenoceptor agonists (ergotamine, dihydroergotamine, isometheptene) were used. The last two decades have witnessed the advent of 5-HT(1B/1D) receptor agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute treatment of migraine. Moreover, current prophylactic treatments of migraine include 5-HT(2) receptor antagonists, Ca(2+) channel blockers, and beta-adrenoceptor antagonists. Despite the progress in migraine research and in view of its complex etiology, this disease still remains underdiagnosed, and available therapies are underused. In this review, we have discussed pharmacological targets in migraine, with special emphasis on compounds acting on 5-HT (5-HT(1-7)), adrenergic (alpha(1), alpha(2,) and beta), calcitonin gene-related peptide (CGRP(1) and CGRP(2)), adenosine (A(1), A(2), and A(3)), glutamate (NMDA, AMPA, kainate, and metabotropic), dopamine, endothelin, and female hormone (estrogen and progesterone) receptors. In addition, we have considered some other targets, including gamma-aminobutyric acid, angiotensin, bradykinin, histamine, and ionotropic receptors, in relation to antimigraine therapy. Finally, the cardiovascular safety of current and prospective antimigraine therapies is touched upon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:378 |
|---|---|
| Enthalten in: |
Naunyn-Schmiedeberg's archives of pharmacology - 378(2008), 4 vom: 02. Okt., Seite 371-94 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mehrotra, Suneet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenergic Agonists |
|---|
| Anmerkungen: |
Date Completed 23.02.2009 Date Revised 20.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00210-008-0322-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM180899783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM180899783 | ||
| 003 | DE-627 | ||
| 005 | 20231223160301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00210-008-0322-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0603.xml |
| 035 | |a (DE-627)NLM180899783 | ||
| 035 | |a (NLM)18626630 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mehrotra, Suneet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current and prospective pharmacological targets in relation to antimigraine action |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2009 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Migraine is a recurrent incapacitating neurovascular disorder characterized by unilateral and throbbing headaches associated with photophobia, phonophobia, nausea, and vomiting. Current specific drugs used in the acute treatment of migraine interact with vascular receptors, a fact that has raised concerns about their cardiovascular safety. In the past, alpha-adrenoceptor agonists (ergotamine, dihydroergotamine, isometheptene) were used. The last two decades have witnessed the advent of 5-HT(1B/1D) receptor agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute treatment of migraine. Moreover, current prophylactic treatments of migraine include 5-HT(2) receptor antagonists, Ca(2+) channel blockers, and beta-adrenoceptor antagonists. Despite the progress in migraine research and in view of its complex etiology, this disease still remains underdiagnosed, and available therapies are underused. In this review, we have discussed pharmacological targets in migraine, with special emphasis on compounds acting on 5-HT (5-HT(1-7)), adrenergic (alpha(1), alpha(2,) and beta), calcitonin gene-related peptide (CGRP(1) and CGRP(2)), adenosine (A(1), A(2), and A(3)), glutamate (NMDA, AMPA, kainate, and metabotropic), dopamine, endothelin, and female hormone (estrogen and progesterone) receptors. In addition, we have considered some other targets, including gamma-aminobutyric acid, angiotensin, bradykinin, histamine, and ionotropic receptors, in relation to antimigraine therapy. Finally, the cardiovascular safety of current and prospective antimigraine therapies is touched upon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adrenergic Agonists |2 NLM | |
| 650 | 7 | |a Adrenergic Antagonists |2 NLM | |
| 650 | 7 | |a Serotonin Antagonists |2 NLM | |
| 650 | 7 | |a Serotonin Receptor Agonists |2 NLM | |
| 700 | 1 | |a Gupta, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Kayi Y |e verfasserin |4 aut | |
| 700 | 1 | |a Villalón, Carlos M |e verfasserin |4 aut | |
| 700 | 1 | |a Centurión, David |e verfasserin |4 aut | |
| 700 | 1 | |a Saxena, Pramod R |e verfasserin |4 aut | |
| 700 | 1 | |a MaassenVanDenBrink, Antoinette |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Naunyn-Schmiedeberg's archives of pharmacology |d 1972 |g 378(2008), 4 vom: 02. Okt., Seite 371-94 |w (DE-627)NLM000008354 |x 1432-1912 |7 nnns |
| 773 | 1 | 8 | |g volume:378 |g year:2008 |g number:4 |g day:02 |g month:10 |g pages:371-94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00210-008-0322-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 378 |j 2008 |e 4 |b 02 |c 10 |h 371-94 | ||